11.5 C
Glasgow
Wednesday, March 18, 2026
spot_img

More News

Enodia Therapeutics acquires preclinical assets from Kezar Life Sciences

Jim Cornall -
Enodia Therapeutics has acquired Kezar Life Sciences’ assets from its Sec61-based discovery and development programme. The acquisition enables Enodia to...

Baseimmune expands into fibrosis

Jim Cornall -
Baseimmune has unveiled its new fibrosis-focused pipeline, beginning with idiopathic pulmonary fibrosis (IPF). IPF is a progressive and life-threatening condition...

Capsule technology opens new window into individual cells

Jim Cornall -
Researchers have developed a capsule-based method that makes it possible to analyse the same cell through multiple experimental steps....

SteerBio launches to find curative therapy for lymphedema

Jim Cornall -
RBL LLC has announced that its portfolio company SteerBio, a biotech startup developing a first-of-its-kind regenerative treatment aimed at...

Severe atopic dermatitis drug sees positive study results

Jim Cornall -
Pfizer Inc. has announced positive topline results from a phase 2 study investigating tilrekimig (PF-07275315) in adults with moderate...

Base to Base biotech podcast 50: Drugs for kidney transplants, glycans, and  drug delivery

Jim Cornall -
As this week’s podcast comes hot on the heels of International Women’s Day and World Kidney Day, which was...

Anti-cancer drug gets phase I FDA trials approval

Jim Cornall -
Great Novel Therapeutics Biotech & Medicals Corporation (GNTbm) says its independently developed novel epigenetic immunoactivator GNTbm-38, for cancer immunotherapy,...

New mass spec platform launched

Jim Cornall -
Nicoya Lifesciences, Inc. has launched FastHDX, a new hydrogen-deuterium exchange mass spectrometry (HDX-MS) platform. FastHDX is the first platform engineered...

Approval for prostate cancer treatment

Jim Cornall -
Johnson & Johnson has announced that the European Commission (EC) has approved an indication extension for AKEEGA (niraparib and...

Approval for atopic dermatitis treatment

Jim Cornall -
Harbour BioMed and Kelun-Biotech have announced that the National Medical Products Administration (NMPA) of China has approved the Investigational...

FDA Breakthrough Therapy Designation for Glanzmann Thrombasthenia drug

Jim Cornall -
The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for Hemab Therapeutics’ drug sutacimig for...

New company targets dry eye disease with first-in-class therapy

Jim Cornall -
26therapeutics Inc., a Canadian life sciences company developing innovative therapies for dry eye disease (DED) and other meibomian gland...

Collaboration to advance novel combination therapy for glioblastoma

Jim Cornall -
INOVIO and Akeso, Inc. have entered into a clinical trial collaboration and supply agreement to evaluate INO-5412, INOVIO's DNA...

Study shows AI boosts breast cancer detection by more than 10 percent

Jim Cornall -
The UK's first comprehensive evaluation of the use of artificial intelligence (AI) in breast cancer screening found that it...

First reliable biomarker test for early kidney transplant rejection detection in living-donor recipients

Jim Cornall -
New analysis in Frontiers in Medicine highlights numares Health’s urinary metabolite constellation as the first biomarker test to show...

Approval for drug to treat advanced squamous cell carcinoma of the anal canal

Jim Cornall -
Incyte has announced that the European Commission (EC) has approved Zynyz (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based...

Naobios and SGS partner to manufacture RSV challenge agent

Jim Cornall -
French CDMO Naobios and SGS are partnering to manufacture a respiratory syncytial virus (RSV) challenge agent for use in...

New approach to drug development

Jim Cornall -
In a recently published review, a research team led by MedUni Vienna has highlighted a promising new approach to...

Base to Base biotech podcast 49: Gene therapy for kidney disease, and using AI to transform diagnostics

Jim Cornall -
This week, we’re chatting with Haseeb Ahmad, CEO of Purespring Therapeutics, about gene therapies in kidney disease, and with...

Antifibrotic drug shows promise for premature ovarian insufficiency

Jim Cornall -
Premature ovarian insufficiency (POI) is a clinically significant cause of infertility that affects between 1 and 3% of women...

Immune cells remember their location

Jim Cornall -
A new AI-based method reconstructs spatial information about where immune cells were originally located in an organ, even after...

Deeptech Digest is your guide to what's new in at the cutting edge of science technology. A bit of artificial intelligence, some biotech, and all the news and latests developments in the field. If it's deeptech, it's in Deeptech Digest!

Contact us: jim@deeptechdigest.com

© 2023 Ayr Coastal Media